» Articles » PMID: 37325452

Multidimensional Futuristic Approaches to Address the Pandemics Beyond COVID-19

Overview
Journal Heliyon
Specialty Social Sciences
Date 2023 Jun 16
PMID 37325452
Authors
Affiliations
Soon will be listed here.
Abstract

Globally, the impact of the coronavirus disease 2019 (COVID-19) pandemic has been enormous and unrelenting with ∼6.9 million deaths and ∼765 million infections. This review mainly focuses on the recent advances and potentially novel molecular tools for viral diagnostics and therapeutics with far-reaching implications in managing the future pandemics. In addition to briefly highlighting the existing and recent methods of viral diagnostics, we propose a couple of potentially novel non-PCR-based methods for rapid, cost-effective, and single-step detection of nucleic acids of viruses using RNA mimics of green fluorescent protein (GFP) and nuclease-based approaches. We also highlight key innovations in miniaturized Lab-on-Chip (LoC) devices, which in combination with cyber-physical systems, could serve as ideal futuristic platforms for viral diagnosis and disease management. We also discuss underexplored and underutilized antiviral strategies, including ribozyme-mediated RNA-cleaving tools for targeting viral RNA, and recent advances in plant-based platforms for rapid, low-cost, and large-scale production and oral delivery of antiviral agents/vaccines. Lastly, we propose repurposing of the existing vaccines for newer applications with a major emphasis on Bacillus Calmette-Guérin (BCG)-based vaccine engineering.

Citing Articles

Animal Cell Lines as Expression Platforms in Viral Vaccine Production: A Post Covid-19 Perspective.

Demirden S, Kimiz-Gebologlu I, Oncel S ACS Omega. 2024; 9(15):16904-16926.

PMID: 38645343 PMC: 11025085. DOI: 10.1021/acsomega.3c10484.


Strategies for the development and approval of COVID-19 vaccines and therapeutics in the post-pandemic period.

Ao D, He X, Liu J, Xu L Signal Transduct Target Ther. 2023; 8(1):466.

PMID: 38129394 PMC: 10739883. DOI: 10.1038/s41392-023-01724-w.


Severity-onset prediction of COVID-19 via artificial-intelligence analysis of multivariate factors.

Fu Y, Zeng L, Huang P, Liao M, Li J, Zhang M Heliyon. 2023; 9(8):e18764.

PMID: 37576285 PMC: 10415884. DOI: 10.1016/j.heliyon.2023.e18764.

References
1.
Kwon K, Verma D, Singh N, Herzog R, Daniell H . Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells. Adv Drug Deliv Rev. 2012; 65(6):782-99. PMC: 3582797. DOI: 10.1016/j.addr.2012.10.005. View

2.
Moorlag S, van Deuren R, van Werkhoven C, Jaeger M, Debisarun P, Taks E . Safety and COVID-19 Symptoms in Individuals Recently Vaccinated with BCG: a Retrospective Cohort Study. Cell Rep Med. 2020; 1(5):100073. PMC: 7405881. DOI: 10.1016/j.xcrm.2020.100073. View

3.
Loutfy M, Blatt L, Siminovitch K, Ward S, Wolff B, Lho H . Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA. 2003; 290(24):3222-8. DOI: 10.1001/jama.290.24.3222. View

4.
Ma J, Drossard J, Lewis D, Altmann F, Boyle J, Christou P . Regulatory approval and a first-in-human phase I clinical trial of a monoclonal antibody produced in transgenic tobacco plants. Plant Biotechnol J. 2015; 13(8):1106-20. DOI: 10.1111/pbi.12416. View

5.
Sullenger B, Cech T . Tethering ribozymes to a retroviral packaging signal for destruction of viral RNA. Science. 1993; 262(5139):1566-9. DOI: 10.1126/science.8248806. View